{"disease":{"id":"ovarian-cancer-metastatic","name":"ovarian cancer metastatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07009743","title":"O-RADS MRI System on Early Detection of Ovarian Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2549,"lead_sponsor_name":"Shanghai Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT03319628","title":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":523,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04330716","title":"Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers","phase":"NA","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT05610501","title":"Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT05032040","title":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02657889","title":"Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT03983954","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NeoTX Therapeutics Ltd.","has_results":false},{"nct_id":"NCT03454451","title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Corvus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07340164","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":116,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07057167","title":"Prediction of Ovarian Cancer Histotypes and Surgical Outcome","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04998760","title":"A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Qi Zhou","has_results":false},{"nct_id":"NCT05827614","title":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Boundless Bio, Inc.","has_results":false},{"nct_id":"NCT06517433","title":"First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT06839144","title":"Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT03907852","title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"TCR2 Therapeutics","has_results":false},{"nct_id":"NCT04726332","title":"Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06010875","title":"A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05092373","title":"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07311577","title":"Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Jiangsu Cancer Institute & Hospital","has_results":false},{"nct_id":"NCT06215950","title":"A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05567601","title":"Doxil/Caelyx BE Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Baxter Healthcare Corporation","has_results":false},{"nct_id":"NCT05074472","title":"A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"ZielBio, Inc.","has_results":false},{"nct_id":"NCT04898842","title":"Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT06264921","title":"A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06825455","title":"Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT03277482","title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06533332","title":"A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"EtiraRx Australia Pty Ltd","has_results":false},{"nct_id":"NCT03689192","title":"Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Herlev Hospital","has_results":true},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04611126","title":"T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Inge Marie Svane","has_results":true},{"nct_id":"NCT06107868","title":"Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05317078","title":"A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05368506","title":"ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06681870","title":"A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT04389229","title":"OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Immetacyte Ltd","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}